Based on the Annovis Bio Inc stock forecast from 3 analysts, the average analyst target price for Annovis Bio Inc is USD 28.00 over the next 12 months. Annovis Bio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Annovis Bio Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Annovis Bio Inc’s stock price was USD 4.37. Annovis Bio Inc’s stock price has changed by -17.70% over the past week, -33.18% over the past month and -59.35% over the last year.
No recent analyst target price found for Annovis Bio Inc
No recent average analyst rating found for Annovis Bio Inc
Company Overview Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania. Read Less
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and ot...Read More
Frequently Asked Questions About Annovis Bio Inc (ANVS) Stock
Based on ratings from 3 analysts Annovis Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANVS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ANVS is USD 28.00 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 21.
ANVS stock's Price/Earning ratio is -99,999.99.
Our analysis grades ANVS stock's Price / Earning ratio at A+. This means that ANVS stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this ANVS may be undervalued for its sector.
The last closing price of ANVS's stock was USD 4.37.
The most recent market capitalization for ANVS is USD 0.07B.
Based on targets from 3 analysts, the average taret price for ANVS is projected at USD 28.00 over the next 12 months.
This means that ANVS's stock price may go up by +540.73% over the next 12 months.
We can't find any ETFs which contains Annovis Bio Inc's stock.
As per our most recent records Annovis Bio Inc has 6 Employees.
Annovis Bio Inc's registered address is 101 Lindenwood Drive, Malvern, PA, United States, 19355.
You can get more information about it from Annovis Bio Inc's website at https://www.annovisbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Negative earnings
The company had negative total earnings in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Annovis Bio Inc (ANVS) Stock
Based on ratings from 3 analysts Annovis Bio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANVS's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for ANVS is USD 28.00 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 21.
ANVS stock's Price/Earning ratio is -99,999.99.
Our analysis grades ANVS stock's Price / Earning ratio at A+. This means that ANVS stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this ANVS may be undervalued for its sector.
The last closing price of ANVS's stock was USD 4.37.
The most recent market capitalization for ANVS is USD 0.07B.
Based on targets from 3 analysts, the average taret price for ANVS is projected at USD 28.00 over the next 12 months.
This means that ANVS's stock price may go up by +540.73% over the next 12 months.
We can't find any ETFs which contains Annovis Bio Inc's stock.
As per our most recent records Annovis Bio Inc has 6 Employees.
Annovis Bio Inc's registered address is 101 Lindenwood Drive, Malvern, PA, United States, 19355.
You can get more information about it from Annovis Bio Inc's website at https://www.annovisbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANVS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
